Graphic: 7 Biosimilars OK’d by FDA

The U.S. Food and Drug Administration to date has approved seven biosimilars, including Zarxio, Inflectra and Erelzi.

A rundown on the seven biosimilars can be seen at left.

(Graphic courtesy of Center for Biosimilars)

You might also be interested in:

Exploring Climate Change Through the Lens of Health Equity 05/25/2022
Call for Papers: Essen Health Conference 02/21/2022
Evidence Partners and Clarivate Form Channel Partnership to… 02/01/2022
Amalgam Rx™ and AWS Collaborate to Accelerate and Simplify… 07/19/2021
Study: Asian-American Health Impacted by Stereotypes and Poor Data 03/17/2022
Telehealth Could Advance Value-based Care in the US 12/15/2021
Course Available: Introduction to Health Economics and… 02/09/2022